SOFT Efficacy and Quality of Life
The addition of ovarian suppression to adjuvant treatment (post-surgery) with tamoxifen reduced breast cancer recurrence in young women with hormone-sensitive early breast cancer who received chemotherapy and had not reached menopause. The addition of ovarian suppression to tamoxifen did not benefit all young women. The International Breast Cancer Study Group (IBSCG) presented results of the randomized, phase III SOFT clinical trial today at the 2014 San Antonio Breast Cancer Symposium and published the results online in the New England Journal of Medicine.
Please contact email@example.com for media inquiries.
SABCS 2014 Oral Presentations
Dr. Prudence Francis presented on behalf of IBCSG at the December 11 general session.
SOFT Quality of Life
Dr. Karin Ribi presented on behalf of IBCSG at the December 11 general session.
New England Journal of Medicine
We are pleased to publish our results in the The New England Journal of Medicine.
- Click here to access the online publication.
SABCS 2014 Related Abstracts
We also presented the following related TEXT and SOFT abstracts:
- TEXT Translational Research
For information on the combined TEXT/SOFT results presented at ASCO 2014, please visit http://www.ibcsg.org/News/Pages/ASCO2014.aspx. Women who participated in the TEXT and SOFT clinical trials should contact their treating physician for additional information.